Skip to main content
. 2014 Dec 19;19(12):21442–21461. doi: 10.3390/molecules191221442

Table 2.

Effect of PCPA, pindolol, WAY100635 and 8OH-DPAT on the immobility time of Km in FST of mice.

Treatment 1 (mg/kg) plus Treatment 2 (mg/kg) Immobility Time (sec)
Experiment I
Vehicle vehicle 57.93 ± 2.02
Vehicle Km (10) 27.73 ± 3.62 **
Pcpa (100) vehicle 50.36 ± 4.52
Pcpa (100) Km(10) 51.26 ± 6.24
H = 10.246, df = 3, p = 0.006
Experiment II
Vehicle vehicle 57.93 ± 2.02
Pindolol (10) Vehicle 59.86 ± 7.83 ###
Vehicle Km (10) 29.11 ± 3.08 ***
Km (10) Pindolol (10) 13.10 ± 2.42 ***, ###
H = 25.77, df = 3, p ≤ 0.001
Experiment III
Vehicle vehicle 52.93 ± 2.02
Way100635 (0.03) vehicle 58.03 ± 5.49
Vehicle Km (10) 29.11 ± 3.08 ***
Way(0.03) Km(10) 54.24 ± 6.85
H = 14.02, df = 3, p = 0.003
Experiment IV
Vehicle vehicle 58.13 ± 2.31
Vehicle Km (1) 60.07 ± 3.82
8OH-DPAT (0.05) vehicle 60.85 ± 3.85 ###
8OH-DPAT (0.5) vehicle 30.78 ± 3.48 ***
8OH-DPAT (0.05) Km (1) 34.91 ± 3.48 ***, ###
H = 30.59, df = 5, p = 0.001

Effects of joint administration of Km and PCPA (100 mg/kg daily, during the 4 days previous to the test; i.p. route), Km (oral route) plus pindolol (i.p.; 10 mg/kg) 30 min before the FST, WAY 100635 at 0.03 mg/kg (s.c.via), 30 min before Km (10 mg/kg) administration and 60 min before the FST. of Km and 8OH-DPAT, were joint administered 30 min before the start of the FST; All results are expressed as the means ± standard error (n = 8–14). Comparisons were made using a Kruskal-Wallis analysis of variance based on rank, followed by the Mann-Whitney-U-test: ** p < 0.01, *** p < 0.001 when compared with control group and ### p < 0.001 when compared with drug alone: PCPA (100) vs. [PCPA (100) plus Km (10)]: T = 80.0, n = 8–11, p = 0.967; Pindolol (10) vs. [Pindolol (10) plus Km (10)]: T = 124.0, n = 8, and n = 11, p ≤ 0.001; WAY100635 vs. [WAY100635 plus Km (10)]: T = 69.0, n = 8, p = 0.958; 8OH-DPAT (0.05) vs. [8OH-DPAT (0.05) plus Km (1)]: T = 98.0, n = 8–12, p ≤ 0.001.